CGBIO Co., Ltd. is a South Korean company specializing in regenerative medicine and biomaterials. It develops and manufactures products for spine care, wound healing, and aesthetics, including lifting threads. The firm operates as an affiliate of Daewoong Pharmaceutical. In 2026, negotiations for a controlling stake acquisition by IMM Private Equity were terminated after failing to reach agreement on terms.
Also known as CG Bio Co., Ltd..
None yet. When a new project in the record names CGBIO as owner, partner or investor, it shows here.
Quarterly sales topped $25.3B; adjusted net earnings and EPS rose, free cash flow improved, and full-year revenue guidance was raised above $100B for the first time.
